No Data
No Data
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a
Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution
In the last year, many Vir Biotechnology, Inc. (NASDAQ:VIR) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it i
Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares
Form 144 | Vir Biotechnology(VIR.US) Officer Proposes to Sell 350.58K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 4, $Vir Biotechnology(VIR.US)$ Officer Pang Phillip intends to sell 37,535 shares of its common stock on Apr 4, with a total market value of approximately $350.58K. Pang
Form 144 | Vir Biotechnology(VIR.US) Insider Proposes to Sell 504.59K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 3, $Vir Biotechnology(VIR.US)$ Insider PHILLIP PANG intends to sell 53,000 shares of its common stock on Apr 3, with a total market value of approximately $504.59K. PHILL
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology with a Buy and maintains $110 price target.
No Data